Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “get” score to a “hold” rating in a research note issued to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on finding and also creating small particle medication prospects to deal with cancer cells. The Company‘s items under various stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts additionally just recently commented on the business. Noble Financial editioned a “acquire” score and released a $11.00 cost goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day relocating ordinary rate of $2.90 as well as a two-hundred day relocating average rate of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, topping experts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and an unfavorable net margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will post -1.18 EPS for the existing year.

A number of hedge funds have actually lately bought and sold shares of ONTX. GSA Resources Allies LLP bought a new setting in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Resources Monitoring LP acquired a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists have 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the recognition as well as growth of oncology therapeutics. It concentrates on discovering and developing small particle medicine prospects to treat cancer cells. The firm was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a totally free copy of the Zacks research report on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, visit Zacks.com.

This instant news alert was produced by narrative scientific research innovation and monetary data from Market in order to offer visitors with the fastest and also most exact coverage. This story was assessed by Market’s editorial team before magazine. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Before you think about Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s premier and best carrying out research experts and also the stocks they recommend to their customers on a daily basis. Market has actually identified the five stocks that top analysts are silently murmuring to their customers to get now before the broader market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” rating amongst analysts, premier experts think these five stocks are much better buys.